Aduro has strong intellectual property positions for all of three our technology platforms. Our portfolio is the most advanced for our Listeria platform and includes a number of issued patents, both in the United States (see below) and in various foreign countries, related to our proprietary Listeria platform. Our intellectual property includes patents and patent applications directed to methods for attenuating the Listeria bacterium to improve its safety in vaccine formulations; methods for expression of disease-related antigens for therapeutic and prophylactic purposes; nucleic acid constructs; and the vaccine bacteria themselves. We have also entered into a number of strategic licensing arrangements with both universities and commercial entities that augment our own patent portfolio and enhance our ability to develop our proprietary Listeria platform.
Issued U.S. Patents:
• 8,287,883 (issued October 16, 2012)
• 7,935,804 (issued May 3, 2011)
• 7,927,606 (issued April 19, 2011)
• 7,842,289 (issued November 30, 2010)
• 7,833,775 (issued November 16, 2010)
• 7,695,725 (issued April 13, 2010)
In addition, we acquired all of the GVAX assets from BioSante Pharmaceuticals, Inc., including intellectual property and cell lines. This new acquisition covers all uses of GVAX vaccines for pancreatic, prostate, breast and colon cancer as well as multiple myeloma and assumes rights to the existing license agreement for melanoma.
Moreover, Aduro has exclusively licensed the only issued
patents covering multiple CDN compositions and methods of use for
application to vaccines. In addition, we have new applications for
STINGVAX for cancer treatment and for new CDN compositions with enhanced
STING signaling and formulation efficiency.